Stamos Capital Partners L.P. Purchases New Shares in Novo Nordisk A/S (NYSE:NVO)

Stamos Capital Partners L.P. bought a new stake in Novo Nordisk A/S (NYSE:NVOFree Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,070 shares of the company’s stock, valued at approximately $524,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of Novo Nordisk A/S by 122.7% in the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after acquiring an additional 6,654,614 shares in the last quarter. Morgan Stanley boosted its holdings in Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after purchasing an additional 4,526,199 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after purchasing an additional 4,350,862 shares during the period. Folketrygdfondet increased its position in Novo Nordisk A/S by 2.7% during the 4th quarter. Folketrygdfondet now owns 8,631,264 shares of the company’s stock worth $892,904,000 after purchasing an additional 225,822 shares during the period. Finally, Polen Capital Management LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $718,995,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $137.33.

Read Our Latest Report on NVO

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $0.48 on Friday, hitting $142.88. The company’s stock had a trading volume of 3,511,197 shares, compared to its average volume of 3,373,314. The stock has a 50 day moving average of $129.73 and a 200-day moving average of $119.00. The company has a market capitalization of $641.18 billion, a price-to-earnings ratio of 49.27, a price-to-earnings-growth ratio of 1.47 and a beta of 0.41. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $143.73. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. As a group, research analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current year.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.